Dutch CRO Viroclinics acquired by PE firm

By Melissa Fassbender contact

- Last updated on GMT

(Image: Viroclinics Biosciences)
(Image: Viroclinics Biosciences)

Related tags: Investment

Viroclinics Biosciences is expanding its service offering – and eyeing acquisition – following an investment by Parcom Capital.

The mid-market private equity (PE) firm Parcom Capital acquired the virology contract research organization (CRO) from Glide Healthcare Partners, which bought a majority stake​ in the company in 2013.

We are entering a new growth phase and the acquisition by Parcom Capital will give us the opportunity to expand our service portfolio​,” Viroclinics Biosciences CEO, Bob van Gemen told Outsourcing-Pharma.com.

With Parcom’s Capital platform, our growth rate is accelerated. This means that we are looking into the option of acquiring other companies with specialist knowledge​.”

van Gemen said potential new services include: vaccine ingredients production, new test development for viral targets, and big data

The major benefit [of the acquisition] is that our service offering is expanded for our customers​,” added van Gemen.

Specifically, Viroclinic – which has more than 100 employees globally – is looking to portfolio in other target areas, such as Hepatitis, Polio, SARS, Avian/ Bird Flu, and Rabies.

Financial details of the acquisition were not disclosed.

Related news

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us


View more